• LAST PRICE
    41.6900
  • TODAY'S CHANGE (%)
    Trending Up0.5800 (1.4108%)
  • Bid / Lots
    27.9900/ 1
  • Ask / Lots
    47.0000/ 1
  • Open / Previous Close
    41.4600 / 41.1100
  • Day Range
    Low 40.6600
    High 41.6900
  • 52 Week Range
    Low 27.9850
    High 50.9900
  • Volume
    291,442
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 41.11
TimeVolumeXENE
08:32 ET70141.52
08:34 ET163141.47
08:52 ET140041.36
08:54 ET10041.515
08:57 ET10041.34
09:19 ET10041.41
09:21 ET10041.49
09:24 ET10041.47
09:33 ET10041.485
09:35 ET10041.485
09:42 ET10041.54
09:44 ET138041.51
09:46 ET20041.48
09:50 ET20041.47
09:51 ET130041.35
09:55 ET20041.38
09:57 ET164041.43
10:00 ET20041.335
10:04 ET4970041.25
10:06 ET90041.13
10:08 ET90040.905
10:09 ET132040.95
10:11 ET40040.82
10:13 ET60041.1
10:15 ET10041.04
10:18 ET30041.17
10:20 ET10041.18
10:22 ET10041.17
10:27 ET30041.27
10:29 ET30041.26
10:31 ET30041.175
10:33 ET10041.18
10:36 ET40041.13
10:40 ET10041.08
10:42 ET20040.89
10:44 ET10040.87
10:49 ET10040.86
11:00 ET10040.885
11:03 ET40040.98
11:05 ET50040.88
11:25 ET22041.0352
11:27 ET30040.86
11:32 ET70040.72
11:34 ET40040.66
11:36 ET10040.725
11:41 ET129740.775
11:43 ET70040.68
11:50 ET233040.715
11:56 ET70640.77
11:59 ET129340.85
12:03 ET110040.835
12:06 ET10040.845
12:10 ET292940.925
12:12 ET10040.93
12:14 ET10040.94
12:15 ET10040.87
12:19 ET150040.89
12:21 ET42040.85
12:26 ET72040.85
12:28 ET40040.875
12:30 ET30040.875
12:32 ET10040.875
12:33 ET24640.76
12:35 ET270040.845
12:37 ET107340.785
12:39 ET10040.825
12:42 ET10040.825
12:44 ET46740.83
12:46 ET70540.79
12:48 ET30040.79
12:57 ET80540.81
01:00 ET20040.79
01:02 ET602940.92
01:06 ET271440.9157
01:08 ET10040.98
01:09 ET20040.96
01:13 ET50040.83
01:15 ET60040.77
01:20 ET20040.87
01:22 ET30040.82
01:26 ET50040.85
01:29 ET70040.8
01:31 ET158440.83
01:33 ET40040.93
01:36 ET10040.94
01:40 ET20040.94
01:47 ET240040.92
01:49 ET30040.92
01:51 ET198040.95
01:54 ET90041.05
01:56 ET60041.17
01:58 ET40041.2
02:00 ET60041.17
02:02 ET40041.2
02:03 ET20041.14
02:07 ET10041.135
02:12 ET10041.18
02:14 ET20041.18
02:16 ET1450041.145
02:18 ET328241.24
02:20 ET10041.24
02:21 ET33841.255
02:23 ET10041.255
02:25 ET61141.21
02:27 ET30041.21
02:30 ET51941.19
02:32 ET39241.175
02:34 ET117841.165
02:36 ET150041.27
02:39 ET50141.301
02:41 ET133541.37
02:43 ET70041.415
02:45 ET51741.47
02:48 ET10041.485
02:50 ET16141.475
02:52 ET97941.4
02:54 ET160041.45
02:56 ET144541.51
02:57 ET256941.555
02:59 ET3470241.69
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXENE
Xenon Pharmaceuticals Inc
3.2B
-15.2x
---
United StatesAPGE
Apogee Therapeutics Inc
3.2B
-24.2x
---
United StatesEWTX
Edgewise Therapeutics Inc
3.2B
-22.2x
---
United StatesVSBC
Vitaspring Biomedical Co. Ltd
3.1B
3,311.3x
---
United StatesMLTX
MoonLake Immunotherapeutics
3.0B
-51.7x
---
United StatesIOVA
Iovance Biotherapeutics Inc
3.4B
-6.7x
---
As of 2024-11-03

Company Information

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.

Contact Information

Headquarters
3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
Phone
604-484-3300
Fax
604-484-3450

Executives

President, Chief Executive Officer, Director
Ian Mortimer
Chief Financial Officer
Sherry Aulin
Executive Vice President - Drug Discovery
James Empfield
Executive Vice President - Strategy and Innovation
Robin Sherrington
Chief Medical Officer
Christopher Kenney

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.2B
Revenue (TTM)
$0.00
Shares Outstanding
75.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.21
EPS
$-2.74
Book Value
$12.31
P/E Ratio
-15.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.